GlassScriptPhysician profile
Huy Duong
NPI 1023003639
$2,238.01
in general payments reported to CMS, 2019-2025
25 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2022: $85.55 · 2023: $963 · 2024: $622 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.26 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $316.74 | 2023-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Mylan Specialty L.P. | $284.25 | 2023-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $160.44 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $155.10 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Insmed, INC. | $143.83 | 2019-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.36 | 2023-2024 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Sunovion Pharmaceuticals INC. | $129.21 | 2019 | |
| Merck Sharp & Dohme LLC | $104.61 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Inspire Medical Systems, INC. | $100.28 | 2023-2025 | Inspire |
| Abiomed | $92.92 | 2024 | Impella |
| Amgen INC. | $84.09 | 2023-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $78.99 | 2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $76.93 | 2022-2024 | |
| Grifols USA, LLC | $76.68 | 2023-2024 | Prolastin-C Liquid |
| Tactile Systems Technology INC | $48.98 | 2023 | Flexitouch Plus, Entre Plus |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $47.95 | 2024-2025 | Fetroja |
| Pfizer INC. | $30.50 | 2022-2023 | |
| Cumberland Pharmaceuticals, INC. | $28.32 | 2024 | Vibativ |
| Ani Pharmaceuticals, INC. | $26.19 | 2024 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $24.48 | 2025 | Ohtuvayre |
| Baxter Healthcare | $23.04 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Optinose US, INC. | $20.95 | 2024 | |
| Axsome Therapeutics, INC. | $16.43 | 2024 | Sunosi |
| Philips North America LLC | $16.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.58 | 2023 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huy Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.